+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the safety of Beyfortus Nirsevimab in children up to 24 months old in South Korea. It is conducted as part of a local risk management plan to collect real-world safety information on Beyfortus when used according to approved indications. The study focuses on children who have received Beyfortus in regular clinical practice and is sponsored by Sanofi. Participants in this single-arm, non-interventional study will be children up to 24 months of age who are scheduled to receive Beyfortus via intramuscular injection as per approved guidelines. The study does not assign treatments but observes children receiving Beyfortus naturally during clinical care. Follow-up will continue for 180 days after the administration of Beyfortus to monitor safety. During the study, participants will be monitored for adverse events, serious adverse events, adverse events of special interest, adverse drug reactions as noted in the product label, and occurrences of respiratory syncytial virus lower respiratory tract infection. Data will be collected through clinical practice visits over the 180-day follow-up period. The study aims to gather comprehensive safety information under real-world conditions for up to nearly four years.

Age: 0Days - 24MonthsAll Genders
1 location
P

Actively Recruiting

Researchers are evaluating the use of rimegepant for intermittent prevention of menstrual migraine in women aged 18 to 45 who experience migraine attacks related to their menstrual cycle. This Phase 3, double-blind, randomized study compares rimegepant with placebo to assess its efficacy and safety during the peri-menstrual period. The study focuses on migraine frequency and severity in women with a history of menstrual migraine and regular menstrual cycles. Participants receive either rimegepant 75 mg orally disintegrating tablets for 7 days during each peri-menstrual period or a matching placebo, along with standard care for acute migraine treatment as needed. The study treatment cycles are repeated over 5 menstrual cycles in the double-blind treatment phase. The study also includes an acute treatment dosing option with rimegepant as needed. During the study, participants will be monitored for changes in the number of migraine and headache days, use of migraine medications, and functional disability related to migraine. Cognitive function is also assessed. Researchers will conduct evaluations over 5 months, covering 5 menstrual cycles, and measure outcomes related to migraine frequency and severity during the peri-menstrual period. Safety and tolerability will be closely monitored throughout the study.

Age: 18Years - 45YearsFEMALEPhase 3
123 locations
E

Actively Recruiting

This research focuses on children aged 5 to less than 9 years with myopia. It aims to study the rebound effect, where myopia progression may accelerate after stopping treatment, and to evaluate the long-term safety of SAT-001, a Software as a Medical Device designed to slow myopia progression in pediatric patients. This study serves as an extension to a previous trial that initially tested SAT-001s effects on myopia progression. Participants from the earlier trial, including both those who received SAT-001 plus single vision spectacles and those who only wore spectacles, will be followed for 6 months. During this extension phase, all participants continue wearing single vision spectacles but will no longer receive SAT-001 treatment. The study will monitor changes in eye measurements to assess any rebound in myopia and to observe safety outcomes after stopping SAT-001. Childrens eye health will be regularly evaluated through measurements of spherical equivalent refractive error and axial length at baseline, 12 weeks, and 24 weeks. Researchers will also observe any adverse effects related to stopping SAT-001. The total participation time in this extension study is 6 months following the completion of the initial trial, allowing for close monitoring of myopia progression and safety.

Age: 5Years - 8YearsAll Genders
5 locations
C

Actively Recruiting

Researchers are evaluating whether the risk of major adverse cardiac events over two years differs between two methods of guiding Percutaneous Coronary Intervention PCI in patients with Left Main Coronary Artery LMCA disease. The study compares Fractional Flow Reserve FFR-guided PCI and angiography-guided PCI to understand which approach may better influence treatment decisions and outcomes for this condition. Participants will be randomly assigned to receive either FFR-guided PCI or angiography-guided PCI. Both procedures involve using drug-eluting stents to treat significant LMCA disease and may include patients with other coronary artery diseases. The study will monitor participants for two years after their procedure, capturing various heart-related events and treatment outcomes during this period. During the two-year follow-up, participants will have clinical visits and assessments to track events such as death, heart attacks, hospitalizations, repeat procedures, stroke, bleeding, and stent problems. Researchers will also evaluate hospital stay length, procedure details, heart function, quality of life related to angina and health, and medication use. The study aims to provide comprehensive information on the safety and effectiveness of both PCI guidance strategies over this time frame.

Age: 20Years +All GendersPhase Not Applicable
49 locations
S

Actively Recruiting

Researchers are studying how the lymphatic system changes before and after radiotherapy in female patients with breast cancer. This observational study focuses on identifying early lymphatic changes that may lead to breast-cancer-related lymphedema BCRL. The goal is to understand lymphatic flow and vessel function using indocyanine green ICG lymphography and to predict swelling or symptoms in the arm after radiotherapy. Participants will undergo ICG lymphography before starting radiotherapy and again within 4 to 6 weeks after completing radiotherapy. Some participants may have additional follow-up imaging at 3, 6, or 12 months. No experimental treatments or placebo groups are involved since all receive radiotherapy as part of their standard breast cancer care. The ICG test involves a small injection of dye under the skin and near-infrared imaging to visualize lymphatic flow. During the study, participants will have imaging assessments, arm circumference and volume measurements, and report any arm discomfort or swelling. Researchers will monitor changes in lymphatic function at baseline, shortly after radiotherapy, and during optional longer-term follow-ups. Participants continue their usual medical and rehabilitation care, and safety monitoring includes observing for rare allergic reactions to the ICG dye. The study is expected to provide insights that may help prevent or reduce lymphedema after breast cancer treatment.

Age: 18Years +FEMALE
1 location
S

Actively Recruiting

Researchers are studying whether the Neuclare medical device can temporarily improve executive function, such as planning and problem-solving, in adults aged 55 to 90 years with mild cognitive impairment or early Alzheimers disease. This multicenter, randomized, double-blind, parallel-group trial evaluates the devices safety and efficacy alongside participants usual cognitive medications. The study is sponsored by Deepsonbio and aims to confirm the devices effect on cognitive abilities using established diagnostic criteria for these conditions. Participants continue their current cognitive therapy medications and are randomly assigned to one of two groups one receives the Neuclare device and the other a sham device that looks and feels similar but does not deliver therapeutic ultrasound. The device is applied to the brain three times per week for four weeks, with each session lasting less than 30 minutes. Both participants and study staff are unaware of group assignments to ensure unbiased results. During the trial, researchers will assess attention, cognitive function, activities of daily living, brain imaging using Amyloid PET-CT, blood biomarkers, and quality of life through questionnaires. Safety and adverse effects will be closely monitored throughout the study. The primary measurement is the change in completion time on the Trail Making Test-A from the start to week 5. Participant involvement lasts about five weeks, including treatment and assessments.

Age: 55Years - 90YearsAll GendersPhase Not Applicable
7 locations
O

Actively Recruiting

This trial studies patients with coronary artery disease who have undergone imaging-guided implantation of drug-eluting stents DES. It compares the safety of a tailored antiplatelet therapy strategyshort dual antiplatelet therapy DAPT followed by P2Y12 inhibitor aloneto the conventional longer DAPT approach. The goal is to see if the tailored strategy reduces bleeding without increasing risks of ischemic events after optimized stent placement guided by intravascular ultrasound IVUS or optical coherence tomography OCT. Participants are randomly assigned to one of two groups the conventional arm receiving 12 months of DAPT aspirin plus clopidogrel for chronic coronary syndrome or aspirin plus ticagrelorprasugrel for acute coronary syndrome, and the tailored arm receiving a shorter DAPT duration 1 month for chronic coronary syndrome or 3 months for acute coronary syndrome followed by P2Y12 inhibitor alone. All stent implantations are optimized by intravascular imaging. Clinical follow-up visits occur at 1 or 3, 6, 12, 18, 24, 36, 48, and 50 months after the procedure. Participants will undergo clinical assessments to monitor ischemic events such as death, heart attack, repeat procedures, and stent thrombosis, as well as bleeding events categorized by standard criteria, all measured at 12 months. Additional evaluations include cardiovascular death, stroke, and stent coverage by OCT in a substudy. Safety and effectiveness endpoints will be analyzed primarily by intention-to-treat. The total study duration extends up to about 50 months with multiple follow-up visits to assess long-term outcomes.

Age: 19Years +All GendersPhase 4
33 locations
S

Actively Recruiting

This research focuses on adults in Korea who have chronic or episodic migraine, a neurological condition causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. The study aims to evaluate the safety and effectiveness of atogepant, a medication approved for preventing migraines, when used in regular clinical settings. Participants will take atogepant oral tablets as prescribed by their doctors, following the approved local guidelines. The study involves approximately 3000 adults who will be observed during their routine medical care while using this medication. There are no additional treatments or burdens beyond what their physicians recommend. During the study, participants will attend their usual clinic or hospital visits up to 12 weeks. Researchers will monitor and record any adverse events, including serious or unexpected reactions, as well as common side effects. The main outcomes focus on safety measures related to atogepant use. The study will continue until May 2029, ensuring thorough observation of participants under typical care conditions.

Age: 19Years +All Genders
36 locations
C

Actively Recruiting

Researchers are assessing the safety and effectiveness of a new drug called tegoprazan a Potassium-Competitive Acid Blocker, P-CAB compared to a standard proton pump inhibitor PPI, rabeprazole, in protecting the stomach and upper digestive tract from bleeding and ulcers. This study involves patients who have heart and vascular diseases and use blood-thinning medications that increase the risk of gastrointestinal GI bleeding. The goal is to determine if tegoprazan is at least as good as rabeprazole over a 12-month period. The study has two main parts. First, a safety surveillance phase enrolls about 300 patients taking tegoprazan daily for six months to monitor for liver issues, increased stomach acid hormone levels, or infections. Then, the main randomized phase will include over 3,300 patients assigned to either tegoprazan 50 mg once daily with placebo rabeprazole or rabeprazole 20 mg once daily with placebo tegoprazan. Both groups will be followed for 12 months while taking their assigned medications. Participants will be regularly checked for GI events like bleeding, ulcers, and stomach pain, as well as cardiovascular events such as heart attack or stroke. The study measures when these events first occur and tracks side effects. Safety is closely monitored through lab tests, symptoms, and medical imaging when needed. The entire trial spans several years, with participants involved for at least 12 months during treatment and follow-up.

Age: 19Years +All GendersPhase 4
45 locations
O

Actively Recruiting

This research focuses on participants who have completed a previous Novartis-sponsored study involving remibrutinib, a drug used in dermatological or allergology conditions. It aims to provide continued access to remibrutinib treatment and monitor long-term safety for up to three years, specifically for those benefiting from the treatment and unable to access it outside clinical trials. Participants will receive remibrutinib tablets at the dose and schedule they last followed in their earlier study. There is no screening period after consent and enrollment at the study site, treatment begins immediately. Participants will return to the study center at least every 16 weeks to receive their medication supply but may come back sooner if needed. Treatment can continue up to three years or until certain conditions such as loss of benefit, withdrawal, pregnancy, or other reasons arise. During the study, participants will have regular visits for medication resupply and monitoring. Researchers will track adverse events and serious adverse events throughout the study duration, approximately seven years, to assess long-term safety. Participation involves ongoing evaluation by the investigator to ensure benefits outweigh risks, with continuous access to treatment under medical supervision.

Age: 12Years - 100YearsAll GendersPhase 3
43 locations

1-10 of 12

1